BR112021015109A2 - Conjugado de fármaco-ligante duplo e uso do mesmo - Google Patents
Conjugado de fármaco-ligante duplo e uso do mesmoInfo
- Publication number
- BR112021015109A2 BR112021015109A2 BR112021015109A BR112021015109A BR112021015109A2 BR 112021015109 A2 BR112021015109 A2 BR 112021015109A2 BR 112021015109 A BR112021015109 A BR 112021015109A BR 112021015109 A BR112021015109 A BR 112021015109A BR 112021015109 A2 BR112021015109 A2 BR 112021015109A2
- Authority
- BR
- Brazil
- Prior art keywords
- linker conjugate
- pharmaceutically acceptable
- acceptable salt
- conjugated compound
- dual drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
conjugado de fármaco-ligante duplo e uso do mesmo. trata-se de um composto conjugado ou um sal farmaceuticamente aceitável do mesmo, que compreende uma carga útil e duas moléculas de alvejamento. também é envolvida uma composição farmacêutica que compreende o composto conjugado ou o sal farmaceuticamente aceitável do mesmo. além disso, estão envolvidos um método para distribuir uma carga útil a um objeto que necessita do mesmo, e um método para tratar uma doença, em que ambos os métodos compreendem administrar ao objeto uma quantidade terapeuticamente eficaz do composto conjugado ou o sal farmaceuticamente aceitável do mesmo, ou a composição farmacêutica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019073962 | 2019-01-30 | ||
CN202010048593 | 2020-01-16 | ||
PCT/CN2020/074117 WO2020156513A1 (zh) | 2019-01-30 | 2020-01-31 | 双配体药物偶联体及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021015109A2 true BR112021015109A2 (pt) | 2022-01-11 |
Family
ID=71840373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021015109A BR112021015109A2 (pt) | 2019-01-30 | 2020-01-31 | Conjugado de fármaco-ligante duplo e uso do mesmo |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220175761A1 (pt) |
EP (1) | EP3903825A4 (pt) |
JP (1) | JP2022518924A (pt) |
KR (1) | KR20210119413A (pt) |
CN (1) | CN113453720A (pt) |
AU (1) | AU2020214507A1 (pt) |
BR (1) | BR112021015109A2 (pt) |
IL (1) | IL285148A (pt) |
MX (1) | MX2021009199A (pt) |
SG (1) | SG11202108182RA (pt) |
TW (1) | TW202100183A (pt) |
WO (1) | WO2020156513A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
AU2022296571A1 (en) * | 2021-06-25 | 2023-12-14 | Coherent Biopharma (Suzhou) , Limited | Ligand-drug conjugate and use thereof |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
AU2022371507A1 (en) * | 2021-10-19 | 2024-05-02 | Coherent Biopharma (Suzhou) Limited | Conjugate drug preparation, preparation method therefor and use thereof |
TW202404643A (zh) * | 2022-04-20 | 2024-02-01 | 大陸商同宜醫藥(蘇州)有限公司 | 化合物及用途 |
WO2023209591A1 (en) * | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
CN116789733A (zh) * | 2022-07-05 | 2023-09-22 | 上海药明合联生物技术有限公司 | 偶联连接子 |
WO2024051794A1 (zh) * | 2022-09-09 | 2024-03-14 | 同宜医药(苏州)有限公司 | 放射性核素偶联药物及其药物组合物和应用 |
WO2024105197A1 (en) * | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Small molecule-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
PL3222617T3 (pl) | 2009-03-19 | 2023-01-02 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
CN106466484B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药(苏州)有限公司 | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 |
CN106433063A (zh) | 2015-08-12 | 2017-02-22 | 普立万聚合体(上海)有限公司 | 含有蓝光阻隔添加剂的混合物 |
CN107412794B (zh) * | 2017-04-17 | 2019-01-04 | 中国医学科学院北京协和医院 | 双靶点显像分子探针及其制备方法和应用 |
CN107970453A (zh) * | 2017-12-05 | 2018-05-01 | 北京林业大学 | 一种叶酸修饰的果胶纳米粒子的双靶向递送方法 |
-
2020
- 2020-01-31 JP JP2021543527A patent/JP2022518924A/ja active Pending
- 2020-01-31 WO PCT/CN2020/074117 patent/WO2020156513A1/zh active Application Filing
- 2020-01-31 EP EP20748044.3A patent/EP3903825A4/en active Pending
- 2020-01-31 KR KR1020217024254A patent/KR20210119413A/ko unknown
- 2020-01-31 AU AU2020214507A patent/AU2020214507A1/en active Pending
- 2020-01-31 MX MX2021009199A patent/MX2021009199A/es unknown
- 2020-01-31 US US17/426,293 patent/US20220175761A1/en active Pending
- 2020-01-31 CN CN202080011608.8A patent/CN113453720A/zh active Pending
- 2020-01-31 BR BR112021015109A patent/BR112021015109A2/pt unknown
- 2020-01-31 SG SG11202108182RA patent/SG11202108182RA/en unknown
- 2020-05-14 TW TW109115998A patent/TW202100183A/zh unknown
-
2021
- 2021-07-27 IL IL285148A patent/IL285148A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202100183A (zh) | 2021-01-01 |
CN113453720A (zh) | 2021-09-28 |
EP3903825A1 (en) | 2021-11-03 |
KR20210119413A (ko) | 2021-10-05 |
WO2020156513A1 (zh) | 2020-08-06 |
IL285148A (en) | 2021-09-30 |
EP3903825A4 (en) | 2023-01-11 |
AU2020214507A1 (en) | 2021-08-19 |
MX2021009199A (es) | 2021-09-08 |
JP2022518924A (ja) | 2022-03-17 |
US20220175761A1 (en) | 2022-06-09 |
SG11202108182RA (en) | 2021-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021015109A2 (pt) | Conjugado de fármaco-ligante duplo e uso do mesmo | |
MX2019012676A (es) | Derivados de 2-aminoquinolina. | |
BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
BR112020019875A8 (pt) | composições tópicas para alívio da dor | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112019011139A2 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
MX2020012997A (es) | Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso. | |
BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
BR112018007947A2 (pt) | uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash | |
ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
BR112023006337A2 (pt) | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer | |
BR112021017303A2 (pt) | Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado | |
WO2015191568A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature | |
BR112022010360A2 (pt) | Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos | |
JOP20210045A1 (ar) | مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها | |
BR112022003762A2 (pt) | Proteínas de fusão terapêuticas | |
BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
BR112018068170A2 (pt) | ácido (2s,4r)-5-(5?-cloro-2?-fluor-[1,1?-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi-isoxazol-5-carboxamido)-2-metilpentanoico cristalino e usos dos mesmos | |
BR112015031835A8 (pt) | agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético |